Dietary Manipulation of Histone Structure and Function

Overview

Journal J Nutrigenet Nutrigenomics

Publisher Karger

Specialties Genetics
Nutritional Sciences

Date 2011 Apr 9

PMID 21474954

Citations 3

Authors

Emily Ho

Roderick H Dashwood

Affiliations

Soon will be listed here.

Citing Articles

Exploring epigenetic strategies for the treatment of osteoporosis.

Yi S, Lim J, Kim K Mol Biol Rep. 2024; 51(1):398.

PMID: 38453825 DOI: 10.1007/s11033-024-09353-4.

The Role of Sulforaphane in Epigenetic Mechanisms, Including Interdependence between Histone Modification and DNA Methylation.

Kaufman-Szymczyk A, Majewski G, Lubecka-Pietruszewska K, Fabianowska-Majewska K Int J Mol Sci. 2015; 16(12):29732-43.

PMID: 26703571 PMC: 4691138. DOI: 10.3390/ijms161226195.

Lysine nutrition in swine and the related monogastric animals: muscle protein biosynthesis and beyond.

Liao S, Wang T, Regmi N Springerplus. 2015; 4:147.

PMID: 25830085 PMC: 4377136. DOI: 10.1186/s40064-015-0927-5.

References

Nian H, Bisson W, Dashwood W, Pinto J, Dashwood R . Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis. 2009; 30(8):1416-23. PMC: 2718078. DOI: 10.1093/carcin/bgp147. View

Kelly W, OConnor O, Krug L, Chiao J, Heaney M, Curley T . Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005; 23(17):3923-31. PMC: 1855284. DOI: 10.1200/JCO.2005.14.167. View

Finnin M, Donigian J, Cohen A, Richon V, Rifkind R, Marks P . Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999; 401(6749):188-93. DOI: 10.1038/43710. View

Davie J . Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003; 133(7 Suppl):2485S-2493S. DOI: 10.1093/jn/133.7.2485S. View

Gore S, Baylin S, Sugar E, Carraway H, Miller C, Carducci M . Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006; 66(12):6361-9. DOI: 10.1158/0008-5472.CAN-06-0080. View

Herman J, Baylin S . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-54. DOI: 10.1056/NEJMra023075. View

Ghoshal K, Bai S . DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 2007; 43(6):395-422. DOI: 10.1358/dot.2007.43.6.1062666. View

Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duee P . Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis. 2004; 25(7):1227-36. DOI: 10.1093/carcin/bgh123. View

Pledgie-Tracy A, Sobolewski M, Davidson N . Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther. 2007; 6(3):1013-21. DOI: 10.1158/1535-7163.MCT-06-0494. View

10.

Seligson D, Horvath S, Shi T, Yu H, Tze S, Grunstein M . Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005; 435(7046):1262-6. DOI: 10.1038/nature03672. View

11.

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

12.

Garcia-Manero G, Issa J . Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 2005; 23(7):635-42. DOI: 10.1080/07357900500283119. View

13.

Juttermann R, Li E, Jaenisch R . Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994; 91(25):11797-801. PMC: 45322. DOI: 10.1073/pnas.91.25.11797. View

14.

Baylin S, Esteller M, Rountree M, Bachman K, Schuebel K, Herman J . Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001; 10(7):687-92. DOI: 10.1093/hmg/10.7.687. View

15.

Wolffe A, Matzke M . Epigenetics: regulation through repression. Science. 1999; 286(5439):481-6. DOI: 10.1126/science.286.5439.481. View

16.

Baylin S, Ohm J . Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006; 6(2):107-16. DOI: 10.1038/nrc1799. View

17.

Myzak M, Hardin K, Wang R, Dashwood R, Ho E . Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis. 2005; 27(4):811-9. PMC: 2276576. DOI: 10.1093/carcin/bgi265. View

18.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay H . Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol. 2007; 212(2):330-44. DOI: 10.1002/jcp.21066. View

19.

Soucek K, Kamaid A, Phung A, Kubala L, Bulinski J, Harper R . Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications. Prostate. 2006; 66(9):954-65. DOI: 10.1002/pros.20416. View

20.

Li L, Carroll P, Dahiya R . Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005; 97(2):103-15. DOI: 10.1093/jnci/dji010. View